Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer.

MLA

Cheung, Carol C., et al. “Canadian ROS Proto-Oncogene 1 Study (CROS) for Multi-Institutional Implementation of ROS1 Testing in Non-Small Cell Lung Cancer.” Lung Cancer (Amsterdam, Netherlands), vol. 160, Oct. 2021, pp. 127–35. EBSCOhost, https://doi.org/10.1016/j.lungcan.2021.08.003.

APA

Cheung, C. C., Smith, A. C., Albadine, R., Bigras, G., Bojarski, A., Couture, C., Cutz, J.-C., Huang, W.-Y., Ionescu, D., Itani, D., Izevbaye, I., Karsan, A., Kelly, M. M., Knoll, J., Kwan, K., Nasr, M. R., Qing, G., Rashid-Kolvear, F., Sekhon, H. S., … Tsao, M.-S. (2021). Canadian ROS proto-oncogene 1 study (CROS) for multi-institutional implementation of ROS1 testing in non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands), 160, 127–135. https://doi.org/10.1016/j.lungcan.2021.08.003

Chicago

Cheung, Carol C, Adam C Smith, Roula Albadine, Gilbert Bigras, Anna Bojarski, Christian Couture, Jean-Claude Cutz, et al. 2021. “Canadian ROS Proto-Oncogene 1 Study (CROS) for Multi-Institutional Implementation of ROS1 Testing in Non-Small Cell Lung Cancer.” Lung Cancer (Amsterdam, Netherlands) 160 (October): 127–35. doi:10.1016/j.lungcan.2021.08.003.